KBI-BIOPHARMA
6.7.2022 13:47:10 CEST | Business Wire | Press release
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/
As demand for innovative biologics and effective biosimilars to treat cancer, infectious diseases, and autoimmune diseases continue to rise in Europe and around the world, developing and manufacturing these and other therapeutics, remains complex and time-consuming. By co-locating in one facility, KBI and Selexis will deliver trusted, streamlined, and cost-effective solutions to help clients confidently advance their investigational therapies.
“The opening of our Geneva facility last month was a major milestone for KBI and Selexis, and we are excited to come together today and commemorate this great achievement,” said Mark W. Womack, CEO of KBI and Selexis. “KBI and Selexis have a long history of success together. Our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products. Our aim has always been to help our clients bring novel and effective therapies to the clinic and the market faster. This facility will help advance that mission.”
The ~94,000 square-foot facility will house new laboratories to support Selexis’ unique technical cell line workflows and KBI’s process development and cGMP manufacturing and quality control with a suite of analytical testing laboratories and cGMP single-use manufacturing trains. The expansion will generate over 300 positions in development, operations, and quality assurance. The ribbon-cutting, held on July 5, was attended by the following:
- Luca Bolliger, VP of the Swiss Biotech Association and President of the Swiss Biotech Success Stories Jury
- Mario Rodriguez, Mayor of Plan-les-Ouates
- Fabienne Fischer, State Councilor - Member of the Geneva government, Head of the economy and employment department (DEE)
“I am delighted with the development of KBI and Selexis' activities in Geneva, which contributes to the development of the life sciences sector in Geneva and reinforces our local ecosystem,” said Councilor Fischer. “It also demonstrates the potential and attractiveness of our region.”
About KBI Biopharma, Inc.
KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005082/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku Launches CT Lab HR160 High-Resolution X-ray CT System1.9.2026 17:00:00 CEST | Press release
- Developed in collaboration with Excillum for battery, semiconductor devices, and advanced materials analysis - Rigaku Corporation, a global solutions partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (Headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), today announced the launch of the CT Lab HR160, a high-resolution X-ray computed tomography (CT) system for battery, semiconductor devices, electronic components, and advanced materials analysis. The system is developed in collaboration with Excillum AB, the global source for X-ray innovation (Headquarters: Stockholm, Sweden; CEO: David Lindblom; “Excillum”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901074099/en/ Photo: CT Lab HR160 High-Resolution X-ray CT System CT Lab HR160 combines Rigaku’s X-ray CT imaging expertise with Excillum’s NanoTube N3 X-ray source. Operating at up to 160 kV to support a wide r
GigaDevice Joins the Zephyr® Project to Foster Global Open-Source Ecosystem1.9.2026 16:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has officially joined the Zephyr® Project, one of the world’s leading open-source real-time operating systems (RTOS). Hosted by the Linux Foundation®, the Zephyr® Project welcomes GigaDevice as a Silver Member, making GigaDevice a dual Silver Member of both the Zephyr® Project and the Linux Foundation. Leveraging its comprehensive GD32 MCU portfolio, GigaDevice will actively participate in the Zephyr® community, promoting deeper integration between its MCU technologies and the global open-source RTOS ecosystem. This will provide customers and developers in industrial, IoT, consumer electronics, and other fields with a more open, standardized, and efficient embedded development environment, while continuing to contribute to the growth of the global embedded open ecosystem and broader access to technology. With the continued evolution of the Internet of
Vivax-Metrotech Partners with Oaktree to Accelerate Strategic Growth1.9.2026 16:00:00 CEST | Press release
Vivax-Metrotech Corporation (“Vivax-Metrotech”), a leading manufacturer of precision locating and inspection devices for utility infrastructure, and Oaktree’s Power Opportunities strategy, today announced a partnership to accelerate Vivax-Metrotech’s growth trajectory and strengthen its leading position. For more than 60 years, Vivax-Metrotech has delivered best-in-class solutions for the utility industry with a focus on underground infrastructure. From its origins in California, the company has expanded across the United States and internationally, developing and supplying locator systems, inspection cameras, and associated digital solutions that help utilities, municipalities, and service providers safely build, maintain, and manage their assets. Today, Vivax-Metrotech is firmly established as a leading player in the U.S. and Global utility locator equipment and inspection device markets. The partnership with Oaktree’s Power Opportunities group will support Vivax-Metrotech’s continue
Mary Kay Unveils New Global Brand Platform – Beauty Is More Beautiful Shared™ – Reclaiming Beauty as a Shared Experience1.9.2026 15:00:00 CEST | Press release
With Largest Consumer-Facing Campaign In Company History Mary Kay Enters Its New Era Of Reach And Impact Today, Mary Kay Inc., the iconic beauty and entrepreneurship brand founded by the bold visionary Mary Kay Ash, announced Beauty Is More Beautiful Shared™, its largest-ever global consumer-facing campaign and a long-term brand strategy designed to drive its next era of growth. Launching across 40 markets worldwide, the campaign reintroduces Mary Kay to a new generation of consumers by celebrating a timeless truth at the heart of the brand: Beauty Is More Beautiful Shared™ and bridging the love for Mary Kay across generations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901735460/en/ Mary Kay announces Beauty Is More Beautiful Shared™, its largest-ever global consumer-facing campaign and a long-term brand strategy designed to drive its next era of growth. (Image Courtesy: Mary Kay Inc.) “Beauty Is More Beautiful Share
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts1.9.2026 15:00:00 CEST | Press release
New unified fraud score is the company’s first combined offering in-market since Visa’s acquisition of FeaturespaceA2A Protect has been shown to reduce over 50% more fraud and help reduce over 40% in unnecessary fraud alerts Visa (NYSE: V), a world leader in digital payments, today announced an enhanced version of A2A Protect, delivering real-time risk insights that help banks stop account-to-account fraud before money leaves customer accounts. The expanded solution introduces a new unified fraud score—Visa’s first in-market integration of Featurespace technology—giving financial institutions faster, clearer signals to detect more fraud while reducing unnecessary alerts. As account-to-account (A2A) payments accelerate globally, A2A transactions are projected to surpass 5.8 trillion by 2028, a 160% increase from 20241. A2A Protect leverages advanced AI and sophisticated transfer learning and gives banks immediate access to critical global risk insights on A2A transactions, without waiti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom